InfuSystem Holdings Inc

InfuSystem Holdings Inc (INFU) Stock Analysis

$13.150

+0.359 (+2.73%)At close

Loading chart…
High
13.590
Open
13.140
VWAP
13.21
Volume
134.96K
Mkt Cap
145.87M
Low
12.895
Amount
1.78M
EV/EBITDA, TTM
9.35

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

AI analysis of InfuSystem Holdings Inc (INFU)

Buy

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Valuation Metrics

The current forward P/E ratio for InfuSystem Holdings Inc (INFU) is 22.73, compared to its 5-year average forward P/E of 68.23.

Forward P/E

Fair
5Y Average P/E
68.23
Current P/E
22.73
Overvalued
139.38
Undervalued
-2.92

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
8.84
Current EV/EBITDA
9.35
Overvalued
11.12
Undervalued
6.56

Forward P/S

Fair
5Y Average P/S
1.43
Current P/S
1.70
Overvalued
1.88
Undervalued
0.98

Alphio AI Price Scenarios for INFU

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%INFU

$7.68

Scenario price

B

Base

Base · 50%INFU

$6.54

Scenario price

B

Bear

Bear · 25%INFU

$6.33

Scenario price

Events Timeline

2026-08-04 (ET)

07:00:00

Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s

07:00:00

Company Reports Q2 Revenue of $36.9M

2026-05-18 (ET)

16:40:00

InfuSystem Approves $20M Stock Repurchase Program

2026-05-07 (ET)

07:30:00

Q1 Revenue at $33.7M, Below Consensus

2026-03-02 (ET)

09:40:00

InfuSystem Trading Resumes

News

INFU FAQ — answered by Alphio AI

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading